A Trial of Varenicline for E-cigarette Cessation
RecruitingPhase 2
Investigating Efficacious E-Cigarette Interventions and Cessation Effects on Cancer-Related Biomarkers: A Randomized Trial of Varenicline in Adults
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * report daily use of an e-cigarette containing nicotine * live in Connecticut or South Carolina Exclusion Criteria: * regular use of other tobacco products besides e-cigarettes * medical contraindications for varenicline use * current treatment for tobacco cessation * lack proficiency in English
About the study
This is randomized, placebo-controlled clinical trial in treatment-seeking adults who report regular e-cigarette use to test the hypothesis that varenicline is efficacious for quitting e-cigarettes.
What is being tested
- Varenicline 1mg BID (drug)
- Placebo (drug)
Sponsor: Yale University · Participants: 326 · Started: Oct 14, 2025
Contact the study team
- Lisa Fucito, PhD · Phone: 2032001470
Official record on ClinicalTrials.gov — NCT07040566
Locations in the U.S.
| Connecticut | Yale Cancer Center/Smilow Cancer Hospital at Yale-New Haven, New Haven |
| South Carolina | Hollings Cancer Center at MUSC (HCC), Charleston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.